Emergency use of nebulized milrinone, a phosphodiesterase 3 inhibitor, in status asthmaticus: a case report in Suriname
Article Sidebar
Main Article Content
Abstract
Data indicate the benefits of phosphodiesterase inhibitors as an add-on treatment in severe asthma, but mainly because of the limited tolerability, no compound reaches the market. Low- and middle-income countries (LMIC) face the challenge of successfully treating status asthmaticus, due to little or no access to expensive drug regimens. We describe a case of a 25-year-old man admitted to the ICU with status asthmaticus where nebulized milrinone was used as a last resort as there was no improvement with optimal standard management. After initiation of nebulized milrinone the patient could be smoothly weaned from ventilation and discharged.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Asthma. World Health Organization. 2022 may [cited 2023 March 6]. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
Afessa B, Morales I, Cury JD. Clinical course and outcome of patients admitted to an ICU for status asthmaticus. Chest. 2001 Nov;120(5):1616-21.
Matera MG, Ora J, Cavalli F, Rogliani P, Cazzola M. New Avenues for Phosphodiesterase Inhibitors in Asthma. J Exp Pharmacol. 2021 Mar 15;13:291-302.
Mincewicz G, Siergiejko G, Piepiorka M, Świdnicka-Siergiejko A, Siergiejko Z, Krzykowski G. Functional assessment of the right ventricle in patients with bronchial asthma of various severity. Postepy Dermatol Alergol. 2021 Feb;38(2):52-56. doi: 10.5114/ada.2021.104278Epub 2021 Mar 10. PMID: 34408566; PMCID: PMC8362787,
Said SI, Hamidi SA, Gonzalez Bosc L. Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis? Eur Respir J. 2010 Apr;35(4):730-4. doi: 10.1183/09031936.00097109. PMID: 20356986; PMCID: PMC2963099.)
Wang H, Gong M, Zhou B, Dai A. Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther. 2009 Apr;26(4):462-8.
Beute J, Lukkes M, Koekoek EP, Nastiti H, Ganesh K, de Bruijn MJ, Hockman S, van Nimwegen M, Braunstahl GJ, Boon L, Lambrecht BN, Manganiello VC, Hendriks RW, KleinJan A. A pathophysiological role of PDE3 in allergic airway inflam-mation. JCI Insight. 2018 Jan 25;3(2):e94888. doi: 10.1172/jci.insight.94888. PMID: 29367458; PMCID: PMC5821178.
Bondarev AD, Attwood MM, Jonsson J, Chubarev VN, Tarasov VV, Liu W, Schiöth HB. Recent developments of phosphodi-esterase inhibitors: Clinical trials, emerging indications and novel molecules. Front Pharmacol. 2022 Nov 24;13:1057083.
Martin C, Burgel PR, Roche N. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review. Int J Chron Obstruct Pulmon Dis. 2021 Aug 16;16:2363-2373.